Cite

    Luber, R. et al. (2021). An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Alimentary pharmacology & therapeutics. 54 (5), pp. 678-688. [Online].